After Novartis' radiotherapy Pluvicto disappoints, CEO touts 'compelling case' for future growth

Even though Novartis grew sales and profits in the last quarter of 2023, the magnitude of the increases was not satisfactory to the Swiss pharma's investors.

Novartis’ fourth-quarter sales grew 10% year over year at constant currencies to $11.4 billion. The number missed analysts’ expectations by 1%, according to the team at ODDO BHF. The company’s stock price fell 3% Wednesday morning as of publication.